Skip to content
  • About Sakar
    • Key Milestones / History
    • Mission, Vision & Values
    • Management Desk
    • Rewards & Recognitions
  • Business
    • Facility
    • Exports
    • Research & Development
    • Quality
    • Future Plans
    • Corporate Social Responsibility
  • General Product
    • Oral – Liquid Syrup & Suspension
    • Liquid Injectable (Svp) – Vials & Ampoules
    • Cephalosporin – Dry Powder Injections
    • Cephalosporin – Oral Solid
    • Lyophilised Injections (In Vials)
  • Oncology Product
    • Oral (Tablet, Capsule, Granules & Liquid)
    • Liquid Injection
    • Lyophilised Injection
    • Active Pharmaceutical Ingredient(Api)
    • CDMO Products
    • CRAMs
  • Clients
  • Investor Relations
    • Financial Reports (Quarterly & Annually)
      • Quarterly
        • Financial Results
        • Investor Presentation
        • Earning Audio Call Recording
        • Earning Call Transcript
        • Shareholding Pattern
        • Press Release
        • Earnings call Invite
        • Factsheet (Quarterly/Annually)
      • Annual
        • Annual Report
      • Subsidiary financials
        • Quarterty
        • Annually
    • Board of Directors
      • Board of Directors
      • Committees
    • Shareholder’s Information
      • Share Price Information From BSE & NSE
      • Notices and Intimations
      • Corporate Announcement
      • Shareholder’s Meet / AGM
      • Credit Rating
      • Policies
    • Corporate Governance
      • Corporate Governance Report
      • Appointment of Committee Members, Key Managerial Positions
      • Documents related to Corporate governance, Compliance
    • Board of Directors
      • Board Of Directors
      • Event Calendar
    • Investor Support
      • Registrar, Company Secretary and Transfer Agent Information
      • Grievance Redressal
      • Reverse Enquiry Toolkit
  • News & Award
    • Rewards & Recognitions
  • Careers
  • Contact Us
  • About Sakar
    • Key Milestones / History
    • Mission, Vision & Values
    • Management Desk
    • Rewards & Recognitions
  • Business
    • Facility
    • Exports
    • Research & Development
    • Quality
    • Future Plans
    • Corporate Social Responsibility
  • General Product
    • Oral – Liquid Syrup & Suspension
    • Liquid Injectable (Svp) – Vials & Ampoules
    • Cephalosporin – Dry Powder Injections
    • Cephalosporin – Oral Solid
    • Lyophilised Injections (In Vials)
  • Oncology Product
    • Oral (Tablet, Capsule, Granules & Liquid)
    • Liquid Injection
    • Lyophilised Injection
    • Active Pharmaceutical Ingredient(Api)
    • CDMO Products
    • CRAMs
  • Clients
  • Investor Relations
    • Financial Reports (Quarterly & Annually)
      • Quarterly
        • Financial Results
        • Investor Presentation
        • Earning Audio Call Recording
        • Earning Call Transcript
        • Shareholding Pattern
        • Press Release
        • Earnings call Invite
        • Factsheet (Quarterly/Annually)
      • Annual
        • Annual Report
      • Subsidiary financials
        • Quarterty
        • Annually
    • Board of Directors
      • Board of Directors
      • Committees
    • Shareholder’s Information
      • Share Price Information From BSE & NSE
      • Notices and Intimations
      • Corporate Announcement
      • Shareholder’s Meet / AGM
      • Credit Rating
      • Policies
    • Corporate Governance
      • Corporate Governance Report
      • Appointment of Committee Members, Key Managerial Positions
      • Documents related to Corporate governance, Compliance
    • Board of Directors
      • Board Of Directors
      • Event Calendar
    • Investor Support
      • Registrar, Company Secretary and Transfer Agent Information
      • Grievance Redressal
      • Reverse Enquiry Toolkit
  • News & Award
    • Rewards & Recognitions
  • Careers
  • Contact Us

Quarter: September 2023

Reconciliation of Share Audit Capital Report for the Quarter ended on September 30, 2023

Certificate Under Reg. 74 (5) of the SEBI Regulations, 2018 for the Quarter Ended 30th September, 2023

Results Publication 30-09-2023

Investor Grievances for the Quarter ended on 30th September 2023

Sakar Healthcare Ltd delivers quality
healthcare solutions worldwide.

Office

  • 406, Silver Oaks Comm. Complex,
    Opp. Arun Society, Paldi, Ahmedabad
    380007 Gujarat – India.
  • info@sakarhealthcare.com
  • 079 – 26588054

Links

  • Key Milestones / History
  • Vision & mission
  • Careers
  • Gallery
  • Exports
  • Contact Us

Products

  • Oral - Liquid Syrup & Suspension
  • Liquid Injectable (Svp) - Vials & Ampoules
  • Oral (Tablet, Capsule, Granules & Liquid)
  • Liquid Injection
Copyright © 2026 Sakar Healthcare Ltd. All Rights Reserved
Powered By : Adit Microsys

Office

  • 406, Silver Oaks Comm. Complex,
    Opp. Arun Society, Paldi, Ahmedabad
    380007 Gujarat – India.
  • info@sakarhealthcare.com
  • 079 – 26588054

Links

  • Home
  • Key Milestones / History
  • Careers
  • Gallery
  • Contact Us

Profile

  • Vision & mission
  • Future Plans
  • Exports
  • Corporate Social Responsibility

Products

  • Oral - Liquid Syrup & Suspension
  • Liquid Injectable (Svp) - Vials & Ampoules
  • Oral (Tablet, Capsule, Granules & Liquid)
  • Liquid Injection
Copyright © 2026 Sakar Healthcare Ltd. All Rights Reserved

Powered By : Adit Microsys

  • Home
  • Prestigious Clients
  • Careers
  • Gallery
  • Enquiry
  • Contact Us

Profile

  • About Us
  • Vision & Mission
  • Exports
  • Future Plans
  • Corporate Social Responsibility

Strength

  • Quality
  • Research & Development
  • Facility

Products

  • Oral - Liquid Syrup & Suspension
  • Liquid Injectable (Svp) - Vials & Ampoules
  • Cephalosporin - Dry Powder Injections
  • Cephalosporin – Oral Solid
  • Lyophilised Injections (In Vials) - EU GMP Approved

Copyright © 2026 Sakar Healthcare Ltd. All Rights Reserved

Powered By : Adit Microsys